COVID-19 Vaccine-Induced Immune Thrombosis with Thrombocytopenia (VITT) and the Shades of Grey in Thrombus Formation

Jecko Thachil

doi:10.1055/s-0041-1735453

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2022; 48(01): 015-018
DOI: 10.1055/s-0041-1735453

Commentary

COVID-19 Vaccine-Induced Immune Thrombosis with Thrombocytopenia (VITT) and the Shades of Grey in Thrombus Formation

Jecko Thachil

¹Department of Haematology, Manchester University Hospitals, Oxford road, Manchester, United Kingdom

› Author Affiliations

Abstract

Full Text

References

References
1 Lippi G, Favaloro EJ. Venous and arterial thromboses: two sides of the same coin?. Semin Thromb Hemost 2018; 44 (03) 239-248
2 Oldenburg J, Klamroth R, Langer F. et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021; 41 (03) 184-189
3 Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Pract Thromb Haemost 2021; 5 (05) e12529
4 Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol 2021; 43 (04) 559-570
5 Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143 (02) 180-190
6 Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link?. Annu Rev Physiol 2011; 73: 527-545
7 Gaertner F, Massberg S. Blood coagulation in immunothrombosis—at the frontline of intravascular immunity. Semin Immunol 2016; 28 (06) 561-569
8 Montoro-García S, Schindewolf M, Stanford S, Larsen OH, Thiele T. The role of platelets in venous thromboembolism. Semin Thromb Hemost 2016; 42 (03) 242-251
9 Undas A, Brummel-Ziedins K, Mann KG. Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thromb Haemost 2014; 12 (11) 1776-1787
10 Becattini C, Agnelli G, Schenone A. et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
11 Brighton TA, Eikelboom JW, Mann K. et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
12 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308 (6923): 235-246
13 Shampo MA, Kyle RA, Steensma DP. John Robert Vane—British pharmacologist and Nobel laureate. Mayo Clin Proc 2013; 88 (07) e71
14 Mazzarello P, Calligaro AL, Calligaro A. Giulio Bizzozero: a pioneer of cell biology. Nat Rev Mol Cell Biol 2001; 2 (10) 776-781
15 Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32 (09) 2045-2051
16 May JE, Moll S. How I treat unexplained arterial thrombosis. Blood 2020; 136 (13) 1487-1498
17 Connolly SJ, Eikelboom JW, Bosch J. et al; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391 (10117): 205-218
18 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
19 Favaloro EJ, Pasalic L, Henry B, Lippi G. Laboratory testing for ADAMTS13: utility for TTP diagnosis/exclusion and beyond. Am J Hematol 2021; 96 (08) 1049-1055
20 Nazy I, Sachs UJ, Arnold DM. et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2021; 19 (06) 1585-1588
21 Handtke S, Wolff M, Zaninetti C. et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood 2021; 137 (26) 3656-3659
22 Thachil J. The prothrombotic potential of platelet factor 4. Eur J Intern Med 2010; 21 (02) 79-83
23 Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 384 (23) 2254-2256
24 Kitchens CS, Erkan D, Brandão LR. et al. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am J Med 2011; 124 (04) 290-296
25 Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998; 104 (04) 381-385
26 Stalker TJ, Traxler EA, Wu J. et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 2013; 121 (10) 1875-1885
27 Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP. Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood 2007; 109 (02) 566-576
28 Harrison P, Savidge GF, Cramer EM. The origin and physiological relevance of alpha-granule adhesive proteins. Br J Haematol 1990; 74 (02) 125-130
29 James EL. Fifty Shades of Grey. London: Vintage Books; 2011